Friday, October 06, 2017 10:15 PM ET
Aimmune Therapeutics (AIMT) sees Significant Insider Selling Continuing
There was a substantial insider sale of Aimmune Therapeutics shares today, as indicated in a filing with the SEC as — Dr Stephen George Dilly, Director and Officer — disposed of 98,846 shares in the company having a market value of approximately $2,593,317 There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 57,460 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 156,306 shares and have averaged 52,102 shares per transaction over this time period.
The number of insider buy/sell trades at Aimmune Therapeutics is above the 19 peer company average over the last 90-day period. The Specialty & Advanced Pharmaceuticals peer group saw 27 buy/sell trades during this period for an average of 1.4 transactions per company. The number of shares per buy/sell trade for Aimmune Therapeutics insiders was also higher. Within the peer group there were 621,842 shares purchased and 103,538 shares sold with company insiders purchasing 24,681 shares on average.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in composing and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.